The deal was originally announced in December 2025. With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) +
The approval allows adults with SLE on standard therapy to inject Saphnelo themselves. It is supported by results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous
The European Commission (EC) has approved Novartis’ Rhapsido (remibrutinib) for certain CSU patients, becoming the first oral treatment for the skin disease. Rhapsido is approved for adult CSU
Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women’s health and general medicines, including biosimilars, reaching 140 countries.
The initiative aims to link external scientific data with internal R&D planning by creating a unified system that supports decision-making, improves market forecasting, and helps prioritise strategic investments.
Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. The partnership aims to establish a robust platform for speciality medicines
The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from
The collaboration aims to implement an agentic platform across MSD’s research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams
The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without suppressing immune
The approval covers Bosaya in a 60mg/ml prefilled syringe and Vevzuo in a 120mg/1.7ml (70mg/ml) single-dose vial, both for subcutaneous injection. Denosumab therapies are used to increase bone
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.